BioCentury | Apr 16, 2021
Finance

April 15 Quick Takes: Co-founded by Springer and Kruse, GPCR play Tectonic raises $80M; plus AltruBio, Rapha, Benchling, BioAge, Amgen

Tectonic Therapeutic debuted with an $80 million series A round co-led by Vida Ventures, T.A. Springer, and Polaris Partners to discover and develop of GPCR-targeted therapies. Tectonic was co-founded in 2019 by Andrew Kruse and Timothy...
BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and...
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 15, 2021
Product Development

Merck’s COVID-19 arsenal continues to dwindle as pharma scraps fusion protein from OncoImmune takeout

Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink Thursday, when the pharma said it would terminate one therapeutic program and end development of another in hospitalized patients with the disease. The pharma...
BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is discontinuing treatment with ICOS agonist feladilimab (GSK3359609) in two Phase II trials for metastatic head and neck squamous cell carcinoma following a recommendation by the independent data monitoring...
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

A study from Guardant Health Inc. (NASDAQ:GH), Amgen Inc. (NASDAQ:AMGN) and academic collaborators showed Guardant’s plasma cell-free DNA (cfDNA)-based Guardant360 CDx test had an 81.5% positive percent agreement and 100% negative percent agreement with a...
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

Shares of Provention Bio Inc. (NASDAQ:PRVB) regained a small bit of the ground they lost Friday, when the stock tumbled 18% to $8 after the company revealed FDA wants more data on its BLA for...
BioCentury | Apr 12, 2021
Product Development

COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

Regeneron reported Phase III data Monday showing subcutaneous REGEN-COV met the primary endpoint of preventing symptomatic COVID-19 in the study’s two populations, and the company plans to request an EUA...
Items per page:
1 - 10 of 12784